<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354222</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2412-J02</org_study_id>
    <nct_id>NCT02354222</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)</brief_title>
  <official_title>Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin in Patients With Inadequate Glycemic Control on Canagliflozin)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of co-administration of
      Canagliflozin (TA-7284) and Teneligliptin (MP-513) once daily for 24 weeks in Japanese
      patients with Type 2 diabetes mellitus who are receiving treatment with Canagliflozin and
      have inadequate glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in HbA1c</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change from Baseline in Fasting Plasma Glucose collected at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change from Baseline in Body Weight collected at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Areas Under the Curve from 0 to 2 h (AUC0-2h) for Postprandial Plasma Glucose</measure>
    <time_frame>0, 0.5, 1, 2 hours post-dose at Baseline and Week 24</time_frame>
    <description>The change from Baseline in AUC0-2h for Postprandial Plasma Glucose collected at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 2-hour Postprandial Plasma Glucose</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change from Baseline in 2-hour Postprandial Plasma Glucose collected at Week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Teneligliptin + Canagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Teneligliptin for 24 weeks in combination with Canagliflozin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Canagliflozin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo for 24 weeks in combination with Canagliflozin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin</intervention_name>
    <arm_group_label>Teneligliptin + Canagliflozin</arm_group_label>
    <arm_group_label>Placebo + Canagliflozin</arm_group_label>
    <other_name>Canagliflozin : Canaglu, TA-7284</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teneligliptin</intervention_name>
    <arm_group_label>Teneligliptin + Canagliflozin</arm_group_label>
    <other_name>Teneligliptin : Tenelia, MP-513</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo + Canagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women who are 20 - 75 years old

          -  HbA1c of ≥7.0% and &lt;10.5%

          -  FPG of ≤ 270 mg/dL

          -  Patients who are under dietary management and taking therapeutic exercise for diabetes
             over 8 weeks before run-in period

        Exclusion Criteria:

          -  Patients with type I diabetes, diabetes mellitus resulting from pancreatic disorder,
             or secondary diabetes

          -  Patients with serious diabetic complications

          -  Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Patients with Class III/IV heart failure symptoms according to New York Heart
             Association (NYHA) functional classification

          -  Patients with severe hepatic disorder or severe renal disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Kadowaki, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tokyo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuoki Kondo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reserch site</name>
      <address>
        <city>Tohoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MT-2412</keyword>
  <keyword>MP-513</keyword>
  <keyword>TA-7284</keyword>
  <keyword>Teneligliptin</keyword>
  <keyword>Canagliflozin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 16, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

